The 22nd MedTech Investing Europe Conferenceeventscase.com/uploads/campdemfile.pdfand leading healthcare investors. In 2015 68% of the attendees purely focused on MedTech, with 32%

The 22nd MedTech Investing Europe Conference

26 & 27 April 2016 The Royal Savoy Hotel, Lausanne, Switzerland

Bringing Together Innovators, Leading Investors and Major Healthcare Corporations

www.medtechinvesting.com

In Partnership with:Organised by: Sponsored By:

Who should attend The delegate profile is made up of the following individuals:

Investors with a focus throughout the life science sector

Senior representatives from major healthcare corporations

Early- to mid-stage companies seeking financing

Family offices and private investors

MedTech service providers

Previous participants by country and sector Regularly attracting over 150 delegates, representing over 20 countries, the MTI conference is the meeting place for break-through technologies and leading healthcare investors. In 2015 68% of the attendees purely focused on MedTech, with 32% investing in MedTech as part of a diverse investment portfolio.

Key statistics from MTI Lausanne 2015

152 Delegates

112 Companies

38 Presenting Companies showcasing their technologies

22 Speakers

22 Countries Represented

250+ Booked One-To-One Meetings

Investor Advisory BoardThe Investor Advisory Board is made up of some of the most pro-active investors in the sector, with over €28bn AUM, they bring their wealth of experience and insight into the MTI series:

Founder & Managing Partner, Panakés Partners, Italy

Partner, Siemens Venture Capital, USA

Partner, Corporate Department, Fisher Broyles, USA

Partner, Gilde Healthcare Partners, Netherlands

Partner, Apposite Capital, UK

CEO & Managing Partner, Ibionext, France

Senior Managing Director, OrbiMed, Israel

Investment Director, Alstin, Germany

About the event Now in its 22nd edition, The MedTech Investing Europe Conference offers a perfect combination of the latest investment opportunities in game-changing technologies and unrivalled programme content giving first-hand insight and opinion from senior-level MedTech experts.

Pre-arranged One-To-One meetings and extensive networking opportunities will give investors and entrepreneurs ample opportunity to identify and meet with the companies and individuals that are right for you. This year’s agenda has been comprehensively researched and designed to cover the most up to date issues within this ever-developing sector and will provide delegates with the vital intelligence and advice needed to succeed in 2016 and beyond.

Consulting / Other VC / Private Equity / Other Private Investors

MedTech Corporate

MedTech Presenting Company

Government / Academia / Industry

Follow us @MTI_Europe for the latest MTI updates and industry news.

Benefits of attending Exclusive access to over 40 pioneering MedTech innovators who will showcase their latest innovations and provide investors with a diverse range of opportunities for investment. The presentations will be streamed for the benefit of the audience and will include product information, stage of business, expected growth rates, exit strategy plans and the level of funding required.

Private One-To-One meetings with the innovators and investors of your choice to discuss potential business opportunities and foster future relationships. Last year over 250 meetings were booked through our online networker, which will allow you to control your conference experience and make the most of your One-To-One meeting time by pre-arranging your twenty minute meetings with MedTech entrepreneurs and other industry leaders. You will also have the opportunity to access company profiles and be able to search by selecting the demographic of your choice.

Exclusive roundtable discussions and keynote presentations have been designed with industry experts to provide you with all the necessary information and guidance you need to flourish in today’s economic climate. Key sessions include:

State of the Nation Address – MedTech’s place with-in the wider healthcare sector

Investment & Sources of Funding – The Beating Heart of the Life Science Sector

Big Data and Digital Healthcare – The Catalyst for New Life Science Technology?

Corporate Investment – Competition or an Essential Route to Market?

Family Office Panel – Extravagant Angel Investors or Long Term Partners?

Commercialisation – How to Dominate Your Market Place

Great peer-to-peer networking opportunities with leading investors, major healthcare corporations and medical technology companies who will all be reunited under one roof, offering a chance to discuss new business opportunities.

These companies are just an example of the ground-breaking investment opportunities available to investors at MTI Lausanne 2016. All the Presenting Companies and their details will be made available to registered delegates.

The MTI events have showcased over 780 companies to our unrivalled audience of investors. Just some of the more recent include:

08:45 – 09:30 Registration, refreshments and networking

09:30 – 09:45 Welcome from the State of VaudRaphaël Conz • Economic Promotion Manager, State of Vaud, Switzerland

09:45 – 10:00 Chairman’s Opening Remarks & State of the Nation Address – MedTech’s Place With-in the Wider Healthcare SectorWith the MTI events having run for over 10 years, we’ve seen many changes in the sector, rotations of investment cycles and shifts in fundraising and investment strategy. So how healthy is MedTech investment at the start of 2016? What does the year ahead hold, what will be the biggest growth areas and the traps investors and entrepreneurs should be concerned about?Benoit Dubuis • President, BioAlps, Switzerland

10:00 – 11:00 Investment & Sources of Funding – The Beating Heart of the Life Science Sector

Today’s entrepreneurial age is giving rise to truly disruptive technologies and companies, but their survival is directly linked to their ability to raise the funding they need. With constantly changing cycles and sources of investment, a clear understanding of investor objectives and strategies is essential. So where is the money coming from and what do different investors want to see?

The positive bigger picture? How is investment in the sector set to change? Family Offices, Angels, VC’s and more – how do their overall strategies differ? What attracts each type of investor to particular investment opportunities? Managing risk – what industry criteria affect the decision to invest?

Moderator: Benoit Dubuis • President, BioAlps, SwitzerlandBali Muralidhar • Partner, MVM Life Science Partners, UKDr Robert Schier • Investment Partner, Seventure, FrancePatrick Burgermeister • Partner, BioMedPartners AG, Switzerland

11:00 – 11:20 Morning coffee and networking opportunity

11:20 – 12:20 MedTech companies pitch their investment opportunities

These sessions are dedicated to MedTech companies presenting innovative technology and investment opportunities in different sectors to an audience of investors. Each company will present for 10 minutes, in ONE of TWO Presentation Rooms.

CONFERENCE PROGRAMME – DAY ONETuesday 26 April 2016

12:20 – 13:20 Big Data and Digital Healthcare – The Catalyst for New Life Science Technology?

Traditionally Big Data has been the preserve of the researcher and Digital Technology has only scratched the surface of what is possible in the medical field, but today both are central pillars of developing new technologies, treatments and healthcare systems. So how can entrepreneurs take advantage of these new advances and what do investors need to be looking out for?

How does data and tech affect the healthcare supply chain, from manufacturer to patient? Restrictions to growth – Can data restrictions and regulation impact growth in these areas? Collaboration with other tech providers, sometimes from outside the healthcare sector, can open up new doors and

markets – how do you forge these partnerships? What does the future hold and what are the key areas of growth?

Moderator: Luc Otten • Partner, Vinci Capital, SwitzerlandAristotelis Nastos • Partner, Creathor Venture Management, GermanyJames Peterson • Former CEO, Haemonetics Corporation, SwitzerlandAlexander Schmitz • Investment Director, Endeavour Vision, Switzerland

13:20 – 14:00 Lunch and networking opportunity



15:10 – 16:10 Corporate Investment – Competition or an Essential Route to Market?

Using the US market as a reference, corporate Venture Capital in Life Sciences is increasing with $1.18bn invested in the first part of 2016. But as budgets outside of VC investment are tightening and R+D strategies are shifting, what are major organisations looking for from start-ups? Will interest and funding in the space from medical and non-medical corporations continue?

How can investments be structured for the success of both the start-up and corporate investor? Cost/benefit analysis – Partner with a major corporate and use their network/resources, or go it alone? How do major corporations define their investment and partnering strategies? What does aligning with a big name mean for existing investors?

Moderator: Frédéric Reymond • Senior Project Director, DEV – Economic Development State of Vaud, SwitzerlandTownsend Goddard • Surgical Division Head, EMEA, Olympus Europa, SwitzerlandGrant Allen • Technology Program Manager & Principal Architect, Google, USAYves Decadt • CEO, Medimetrics & Co-Founder, BioLingus, NetherlandsAnne E. Sissel • Managing Director, Baxter Ventures, USA

16:10 – 16:30 Afternoon coffee and networking opportunity

16:30 – 18:00 One-To-One Meetings: Special pre-scheduled individual One-To-One meetings will be taking place in our dedicated meeting area. This session will consist of 4 x 20min One-To-One meetings.

18:00 – 19:00 Networking Drinks ReceptionThis will be an informal reception allowing you to network with all attendees, building and extending valuable networks.

08:30 – 09:30 Registration, breakfast refreshments and informal networking

09:30 – 09:45 Chairman’s Day Two Opening Remarks Benoit Dubuis • President, BioAlps, Switzerland

09:45 – 11:00 Family Office Panel & Private Wealth Panel – Extravagant Angel Investors or Long Term Partners?

Speak to most start-ups currently in fund-raising mode and they will highlight family offices and private wealth holders as a key target investor group. But what motivates these often private and specialist investors? How do families build successful investment strategies and what are they looking for in healthcare investment?

Defining the family office – Do single family office and multi-family office strategies differ? Does the private nature of family offices fit well with companies looking to guard IP? Doing good - How can a philanthropic investment strategy be fulfilled in MedTech? What do family and private wealth investors offer beyond financial resources?

Moderator: Joanne Sawicki, Director, Isocell Laboratories, UKPatrick Aisher • Director, Kinled Holdings, Hong KongThierry Chignon • Senior Partner, Merieux Developpement, FranceMilan Despotovic • Partner, Aris Wealth Management S.A., SwitzerlandRobert Taub • Private Investor and Entrepreneur, Belgium

11:00 – 11:30 Morning coffee and networking opportunity



12:45 – 13:45 Lunch and networking opportunity

13:45 – 14:45 Commercialisation – How to Dominate Your Market Place

The funding round is complete and now the focus for the company and its investors moves to, amongst other key areas, achieving the sales targets. But getting a new technology into market is not always as straight forward as it should be. What support is available, how reliable are initial sales projections and how can companies ensure an uptake of their technology?

Reimbursement pathways – choosing the right route to market How does regulation in different countries affect the route to commercialisation? The importance of price – is a buyer’s decision always about cost savings? Tips for how a new technology can take-on the competition

Moderator: Corinne Lebourgeois • Managing Director, Med C. Partners, SwitzerlandDavid Porter • Partner, Apposite Capital, UKBeat Steffen • Founder & CEO, Confinis AG, SwitzerlandManfred Ulmer-Weber • Senior Investment Manager, SHS GmbH, Germany

14:45 – 14:55 Chairman’s Closing Remarks

As the 22nd MedTech Investing Europe Conference draws to a close, what does the future hold for both investors and entrepreneurs alike? Whether it’s continuing to raise finances, embark on commercialisation or develop your portfolio of investments, how can your strategy be developed to meet all future challenges and opportunities head-on and ensure you are part of the continuing MedTech revolution.Benoit Dubuis • President, BioAlps, Switzerland

CONFERENCE PROGRAMME – DAY TWOWednesday 27 April 2016

Our company has worked with Campden for several years. Campden has a track record of running high-calibre conferences,

attended by the kind of people we want to meet, in many different parts of the world.Liam Halligan, Chief Economist, Prosperity Capital Management, UK

The conference was well run and interesting, and I enjoyed attending. The number and range of Presenting Companies and their investment opportunities was superb.

Carlos Pittol, Director, Clubb Capital, UK

It was a great opportunity for us to connect with European companies we have not met yet and expand our global investment portfolio.

Kazuki Sakamoto, Associate Manager, Teijin Limited, Japan

Thank you for two great days – I really enjoyed talking to the potential investors and the other entrepreneurs, I met some fabulous people.

Odd Viking Höglund, CEO, Resorbable Devices AB, Sweden

Congratulations on hosting an effective and well-attended meeting – it was fun to be involved with it again.

Dave Hampton, Senior Associate, Cambridge University, UK

“

14:55 – 15:00 Best in Show Presenting Company Awards

Voted for by the audience and attendees, these awards recognise the Presenting Companies who offer the most exciting, ground-breaking and disruptive technologies accompanied by the management teams and business models that will enable these winning companies to continue to grow into world-beating organisations.

15:00 – 16:45 One-To-One Meetings: Special pre-scheduled individual One-To-One meetings will be taking place in our dedicated meeting area. This session will consist of 5 x 20min One-To-One meetings.

For delegates wishing to hold additional ad hoc meetings, designated meeting space will be available at the venue beyond the official close of the conference.

16:45 End of conference

“

“

”

”

”

Feedback from previous MedTech Investing Europe events:

“”

”“

Ticket Options

Early Bird Discount: £999 / €1285 (book before 29 January 2016)

Standard Price: £1495 / €1923 (from 30 January 2016)

Non-Qualifying Investor Ticket: £2000 / €257220% VAT will be added where applicable

Please visit our website for more information or email [email protected]

How to RegisterVisit www.medtechinvesting.com and click on ‘Book Now’

Email: [email protected]: +44 (0)203 763 2800

Interested in becoming a Presenting Company?Present your investment opportunity to an audience of private investors, venture capital and private equity partners and blue-chip corporations.

For more information on Presenting Company opportunities please contact:Alistair Wilmot on +44(0)203 763 2800 or email [email protected]

Organised by:

30 Cannon Street, London EC4M 6XH Tel: +44 (0)203 763 2800

[email protected] www.medtechinvesting.com

The 22nd MedTech Investing Europe Conference

@MTI_Europe#MTIL16

Documents

The 22nd MedTech Investing Europe Conferenceeventscase.com/uploads/campdemfile.pdfand leading healthcare investors. In 2015 68% of the attendees purely focused on MedTech, with 32%